Interestingly, we observed a favorable response to anti-PD1 plus TKI combination therapy in two ASPSCR1-TFE3 fusion tRCC patients in this study. Here, TFE3 is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.